Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB lessened its holdings in Becton, Dickinson and Company (NYSE:BDXFree Report) by 6.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 95,000 shares of the medical instruments supplier’s stock after selling 7,000 shares during the quarter. Becton, Dickinson and Company accounts for approximately 2.6% of Rhenman & Partners Asset Management AB’s holdings, making the stock its 10th biggest holding. Rhenman & Partners Asset Management AB’s holdings in Becton, Dickinson and Company were worth $25,081,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Townsend Asset Management Corp NC ADV increased its position in Becton, Dickinson and Company by 3.4% during the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 1,189 shares of the medical instruments supplier’s stock valued at $314,000 after purchasing an additional 39 shares during the period. FirstPurpose Wealth LLC increased its position in Becton, Dickinson and Company by 2.2% during the 2nd quarter. FirstPurpose Wealth LLC now owns 1,840 shares of the medical instruments supplier’s stock valued at $486,000 after purchasing an additional 40 shares during the period. Breakwater Capital Group increased its position in Becton, Dickinson and Company by 2.6% during the 2nd quarter. Breakwater Capital Group now owns 1,597 shares of the medical instruments supplier’s stock valued at $422,000 after purchasing an additional 40 shares during the period. Ropes Wealth Advisors LLC boosted its holdings in shares of Becton, Dickinson and Company by 0.5% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 8,901 shares of the medical instruments supplier’s stock worth $2,350,000 after buying an additional 41 shares in the last quarter. Finally, Intercontinental Wealth Advisors LLC boosted its holdings in shares of Becton, Dickinson and Company by 2.8% during the 2nd quarter. Intercontinental Wealth Advisors LLC now owns 1,521 shares of the medical instruments supplier’s stock worth $402,000 after buying an additional 42 shares in the last quarter. Institutional investors own 86.72% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Piper Sandler cut their price target on Becton, Dickinson and Company from $305.00 to $280.00 and set an “overweight” rating on the stock in a report on Friday, November 10th. Morgan Stanley increased their price target on Becton, Dickinson and Company from $295.00 to $310.00 and gave the stock an “overweight” rating in a report on Friday, August 4th. StockNews.com assumed coverage on Becton, Dickinson and Company in a report on Thursday, October 5th. They set a “hold” rating on the stock. Citigroup cut their price target on Becton, Dickinson and Company from $282.00 to $260.00 in a report on Monday, October 2nd. Finally, Barclays increased their target price on Becton, Dickinson and Company from $284.00 to $303.00 and gave the stock an “overweight” rating in a report on Monday, August 7th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $282.38.

Check Out Our Latest Analysis on Becton, Dickinson and Company

Becton, Dickinson and Company Stock Up 1.0 %

NYSE:BDX traded up $2.35 during trading hours on Tuesday, hitting $236.02. 600,734 shares of the company traded hands, compared to its average volume of 1,184,927. The company has a quick ratio of 0.81, a current ratio of 1.31 and a debt-to-equity ratio of 0.57. The firm’s 50-day simple moving average is $255.79 and its 200-day simple moving average is $260.43. Becton, Dickinson and Company has a one year low of $228.62 and a one year high of $287.32. The company has a market cap of $68.47 billion, a PE ratio of 47.11, a PEG ratio of 1.88 and a beta of 0.55.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last announced its quarterly earnings data on Thursday, November 9th. The medical instruments supplier reported $3.42 earnings per share for the quarter, hitting the consensus estimate of $3.42. Becton, Dickinson and Company had a return on equity of 13.91% and a net margin of 7.66%. The company had revenue of $5.09 billion during the quarter, compared to analyst estimates of $5.02 billion. During the same quarter last year, the firm posted $2.75 EPS. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. Equities analysts predict that Becton, Dickinson and Company will post 12.84 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be issued a $0.95 dividend. The ex-dividend date of this dividend is Thursday, December 7th. This represents a $3.80 annualized dividend and a yield of 1.61%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.91. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 73.39%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Richard Byrd sold 459 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $274.48, for a total value of $125,986.32. Following the completion of the transaction, the executive vice president now owns 3,444 shares in the company, valued at approximately $945,309.12. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Becton, Dickinson and Company news, Director Claire Fraser sold 848 shares of the firm’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $281.66, for a total value of $238,847.68. Following the completion of the transaction, the director now owns 21,608 shares in the company, valued at approximately $6,086,109.28. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Richard Byrd sold 459 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $274.48, for a total value of $125,986.32. Following the completion of the transaction, the executive vice president now owns 3,444 shares of the company’s stock, valued at approximately $945,309.12. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by insiders.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.